Unibest

Pharmaceutical intermediates

Atogepant Intermediates

3 pharmaceutical intermediates for Atogepant. Indication: Migraine.

提交项目All intermediates

About Atogepant

Originator
Merck & Co Inc
Indication
Migraine
Approved Date
09/28/2021
NCE Patent
09/28/2026
DS/DP
11/10/2031

Available intermediates

3 intermediates currently listed for Atogepant. Request specifications, documentation or a quotation for any item below.

Atogepant intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
L-Phenylalanine, N-acetyl-, compd. with (3S,5S,6R)-3-amino-6-methyl-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)-2-piperidinone (1:1)1456803-45-4//
1456803-42-11456803-42-1//
tert-butyl ((3S,5S,6R)-6-methyl-2-oxo-5-(2,3,6-trifluorophenyl)piperidin-3-yl)carbamate1456803-43-2//

Other programs under A

AbemaciclibAbrocitinibAcalabrutinibAdagrasibAfatinibAfoxolanerAlectinib HydrochlorideAlfacalcidol

Building toward Atogepant?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →